These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 6364432)

  • 41. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.
    Hamad OA; Mitroulis I; Fromell K; Kozarcanin H; Chavakis T; Ricklin D; Lambris JD; Ekdahl KN; Nilsson B
    Thromb Haemost; 2015 Nov; 114(6):1207-17. PubMed ID: 26293614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aplastic anaemia and paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored proteins on human platelets.
    Vu T; Griscelli-Bennaceur A; Gluckman E; Sigaux F; Carosella ED; Menier C; Scrobohaci ML; Socié G
    Br J Haematol; 1996 Jun; 93(3):586-9. PubMed ID: 8652377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evans' syndrome in paroxysmal nocturnal hemoglobinuria.
    Conti L; Iurlo A; Gandolfo GM; Girelli G
    Acta Haematol; 1985; 73(4):210-1. PubMed ID: 3933242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The tick-over theory revisited: is C3 a contact-activated protein?
    Nilsson B; Nilsson Ekdahl K
    Immunobiology; 2012 Nov; 217(11):1106-10. PubMed ID: 22964236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A two-stage immunoradiometric assay with 125I-staphylococcal protein A for the detection of antibodies and complement on human blood cells.
    Salama A; Mueller-Eckhardt C; Bhakdi S
    Vox Sang; 1985; 48(4):239-45. PubMed ID: 3984309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor.
    Parker CJ; Stone OL; Bernshaw NJ
    J Immunol; 1989 Jan; 142(1):208-16. PubMed ID: 2909615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombocytopenia and platelet microvesicle formation caused by Legionella pneumophila infection.
    Larsson A; Nilsson B; Eriksson M
    Thromb Res; 1999 Dec; 96(5):391-7. PubMed ID: 10605954
    [No Abstract]   [Full Text] [Related]  

  • 48. [Complement system regulation and C3 glomerulopathy].
    Xiao HJ; He RJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):323-6. PubMed ID: 23591359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human platelet-initiated formation and uptake of the C5-9 complex of human complement.
    Zimmerman TS; Kolb WP
    J Clin Invest; 1976 Jan; 57(1):203-11. PubMed ID: 812888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chlorpropamide-induced immune hemolytic anemia.
    Logue GL; Boyd AE; Rosse WF
    N Engl J Med; 1970 Oct; 283(17):900-4. PubMed ID: 5458054
    [No Abstract]   [Full Text] [Related]  

  • 51. THE INITIATION AND ENHANCEMENT OF HUMAN RED CELL LYSIS BY ACTIVATORS OF THE FIRST COMPONENT OF COMPLEMENT AND BY FIRST COMPONENT ESTERASE; STUDIES USING NORMAL RED CELLS AND RED CELLS FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.
    YACHNIN S; RUTHENBERG JM
    J Clin Invest; 1965 Apr; 44(4):518-34. PubMed ID: 14278168
    [No Abstract]   [Full Text] [Related]  

  • 52. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
    Logue GL; Rosse WF; Adams JP
    J Clin Invest; 1973 May; 52(5):1129-37. PubMed ID: 4700488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The control of complement activation by the blood cells in paroxysmal nocturnal hemoglobinuria.
    Rosse WF
    Blood; 1986 Feb; 67(2):268-9. PubMed ID: 2417643
    [No Abstract]   [Full Text] [Related]  

  • 54. Human erythrocytes inhibit complement-mediated solubilization of immune complexes.
    Dorval BL; Cosio FG; Birmingham DJ; Hebert LA
    J Immunol; 1989 Apr; 142(8):2721-7. PubMed ID: 2522967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paroxysmal nocturnal hemoglobinuria. Alternate-complement-pathway-mediated lysis induced by magnesium.
    May JE; Rosse W; Frank MM
    N Engl J Med; 1973 Oct; 289(14):705-9. PubMed ID: 4727529
    [No Abstract]   [Full Text] [Related]  

  • 57. Paroxysmal nocturnal hemoglobinuria revisited.
    Schreiber AD
    N Engl J Med; 1983 Sep; 309(12):723-5. PubMed ID: 6888445
    [No Abstract]   [Full Text] [Related]  

  • 58. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 60. [Evaluation and quantification of complement-sensitive red cells in PNH and aplastic anemia-PNH syndrome].
    Shichishima T; Terasawa T; Uchida T; Kariyone S
    Rinsho Ketsueki; 1989 Mar; 30(3):297-302. PubMed ID: 2769953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.